Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuti (NQ: IRWD )

4.190 +0.240 (+6.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuti

< Previous 1 2 3 4 5 6 Next >
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
Investors indicated approval of the company's upcoming $1 billion asset purchase. 
Via The Motley Fool
Ironwood Scoops Up Gastrointestinal Diseases Player For $1B
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has agreed to acquire VectivBio Holding AG (NASDAQ: VECT) for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of... 
Via Benzinga
Why Shares of VectivBio Holding Are Up Today
A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock. 
Via The Motley Fool
Recap: Ironwood Pharmaceuticals Q1 Earnings
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Outlook For Ironwood Pharmaceuticals
Via Benzinga
Merger Monday
This morning, Chevron announced a deal to acquire PDC Energy for $72 per share in stock. 
Via Talk Markets
Why VectivBio Shares Are Surging Monday
VectivBio Holding AG (NASDAQ: VECT) shares are trading higher Monday after GI-focused healthcare company Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) agreed to 
Via Benzinga
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
Both companies are working on treatments for gastrointestinal diseases. 
Via Investor's Business Daily
Benzinga Pro's Top 5 Stocks To Watch For Monday, May 22, 2023: MU, RKT, DLTR, LDOS, IRWD
Micron Technology (MU) - Shares were down about 4% Monday morning following a report the Chinese government found cybersecurity issues related to Micron's products. Chinese officials have asked 
Via Benzinga
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
3 No-Brainer Stocks to Buy Right Now for Less Than $25
All three healthcare stocks are showing solid long-term potential. 
Via The Motley Fool
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Why Ironwood Pharmaceuticals Shares Are Falling During Monday's Session
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares are trading lower by 10.00% to $11.30 Monday afternoon after the company cut its FY22 sales guidance below analyst estimates and issued FY23 sales... 
Via Benzinga
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals: Q3 Earnings Insights
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.